Liquidia Stock Plummets as Analysts Slash Price Targets Following Patent Court Ruling

Liquidia shares declined an additional 14% after Bank of America and other major analysts slashed their price targets following a Delaware court ruling that the company's Yutrepia drug infringes a United Therapeutics patent. The court has not yet determined the remedy, which could range from a simple label modification to a broader restriction on the drug's distribution, and both parties must submit their proposals within one week. Despite the steep analyst cuts, the revised targets remain substantially above the current share price, suggesting some analysts maintain conviction in the company's recovery prospects.

Liquidia's Yutrepia faces significant regulatory uncertainty following the patent infringement finding. The company holds approval for two separate respiratory conditions: pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The court's remedy decision will determine whether Liquidia must simply remove one indication from marketing materials or faces broader distribution constraints that could substantially limit the drug's commercial viability.

The disconnect between current share valuations and analyst targets reflects market skepticism about the company's prospects. Even after substantial downward revisions by major investment banks, projected price targets remain 50-100% above current trading levels, suggesting analysts expect recovery value that investors have not yet priced in—likely due to lingering uncertainty about final court remedies and potential appeal outcomes.